NCT02985983 is a Phase 3 clinical trial of Brodalumab in Axial Spondyloarthritis, sponsored by Kyowa Kirin Co., Ltd..

Who is sponsoring NCT02985983?

NCT02985983 is sponsored by Kyowa Kirin Co., Ltd..

What drugs are being tested in NCT02985983?

Interventions in NCT02985983: Brodalumab, Placebo.

What condition does NCT02985983 study?

NCT02985983 studies Axial Spondyloarthritis.

Is NCT02985983 still recruiting?

NCT02985983 is currently completed. Last updated 16 July 2024.

Last reviewed 2024-07-16 · How we verify

NCT02985983

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Brodalumab in Subjects With Axial Spondyloarthritis (axSpA)

Completed Phase 3 Last updated 16 July 2024

What this trial tests

Phase 3 trial testing Brodalumab in Axial Spondyloarthritis in 159 participants. Completed in 23 September 2019.

Timeline

7 March 2017

Primary endpoint
23 September 2019

23 September 2019

Quick facts

Lead sponsor	Kyowa Kirin Co., Ltd.
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	159
Start date	7 March 2017
Primary completion	23 September 2019
Estimated completion	23 September 2019
Sites	48 locations across Taiwan, Japan, South Korea

Drugs / interventions tested

Brodalumab (BRODALUMAB) — full drug profile →
Placebo

Conditions studied

Axial Spondyloarthritis — all drugs for Axial Spondyloarthritis →

Sponsor

Kyowa Kirin Co., Ltd. — full company profile →

Who can join

18 and older, any sex, with Axial Spondyloarthritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the efficacy of Brodalumab in axSpA (ankylosing spondylitis \[AS\] and non-radiographic axial spondyloarthritis \[nr-axSpA\]) subjects compared to placebo, as measured by the proportion of axSpA subjects achieving an Assessment of SpondyloArthritis international Society (ASAS) 40 response at week 16.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

The role of inflammation in autoimmune disease: a therapeutic target.
Xiang Y, Zhang M, Jiang D, Su Q, et al · · 2023 · cited 104× · PMID 37859999 · DOI 10.3389/fimmu.2023.1267091
Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial.
Wei JC, Kim TH, Kishimoto M, Ogusu N, et al · · 2021 · cited 49× · PMID 33827787 · DOI 10.1136/annrheumdis-2020-219406
Targeting inflammatory pathways in axial spondyloarthritis.
Furst DE, Louie JS. · · 2019 · cited 34× · PMID 31164157 · DOI 10.1186/s13075-019-1885-z
Role of Interleukin- (IL-) 17 in the Pathogenesis and Targeted Therapies in Spondyloarthropathies.
Chyuan IT, Chen JY. · · 2018 · cited 25× · PMID 29670461 · DOI 10.1155/2018/2403935
Anti-IL-17 Agents in the Treatment of Axial Spondyloarthritis.
Atzeni F, Carriero A, Boccassini L, D'Angelo S. · · 2021 · cited 21× · PMID 33977094 · DOI 10.2147/itt.s259126
The 2023 pipeline of disease-modifying antirheumatic drugs (DMARDs) in clinical development for spondyloarthritis (including psoriatic arthritis): a systematic review of trials.
Denis A, Sztejkowski C, Arnaud L, Becker G, et al · · 2023 · cited 17× · PMID 37507210 · DOI 10.1136/rmdopen-2023-003279
Brodalumab, an anti-interleukin-17 receptor A monoclonal antibody, in axial spondyloarthritis: 68-week results from a phase 3 study.
Kim TH, Kishimoto M, Wei JC, Jeong H, et al · · 2023 · cited 12× · PMID 36130275 · DOI 10.1093/rheumatology/keac522
Recent advances in managing axial spondyloarthritis.
Agrawal P, Machado PM. · · 2020 · cited 6× · PMID 32704350 · DOI 10.12688/f1000research.22577.1

Verify or expand the search:

Other trials of Brodalumab

Trials testing the same drug.

NCT04305327 — Efficacy and Safety of Brodalumab in Adolescents From 12 to 17 Years of Age With Moderate-to-severe Plaque Psoriasis · Phase 3 · terminated
NCT04306315 — Adjusted Brodalumab Dose Compared With Standard Brodalumab Dose in Subjects With Moderate-to-severe Plaque Psoriasis and · Phase 4 · completed
NCT05132231 — Canadian Real World Evidence Study of Brodalumab in Plaque Psoriasis to Understand the Impact on Quality of Life and Wor · active not recruiting
NCT04979520 — Molecular Characteristics of Brodalumab in Hidradenitis Suppurativa · EARLY_PHASE1 · completed
NCT04533737 — Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Respons · Phase 4 · terminated

Other recruiting trials for Axial Spondyloarthritis

Currently open trials in the same condition.

NCT07087912 — Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases · Phase 4 · recruiting
NCT07290036 — A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adu · Phase 1 · recruiting
NCT06888193 — A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® · Phase 1 · recruiting
NCT07414823 — Walking Football for Axial Spondyloarthritis · NA · active not recruiting
NCT07148414 — A Study of SPY072 in Rheumatic Disease · Phase 2 · recruiting

Other Kyowa Kirin Co., Ltd. trials

Trials by the same sponsor.

NCT06926491 — Evaluate the Efficacy and Safety of KK8398 in Patients With Achondroplasia（AOBA Study） · Phase 3 · recruiting
NCT06812104 — Clinical Trial of KK2845 in Patients With Relapsed or Refractory Acute Myeloid Leukemia · Phase 1 · recruiting
NCT06525636 — A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia · Phase 1, PHASE2 · recruiting
NCT06116890 — Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration · Phase 2 · active not recruiting
NCT06116916 — Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema · Phase 2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02985983 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Kyowa Kirin Co., Ltd.
Last refreshed: 16 July 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02985983.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing